Results 91 to 100 of about 1,393 (218)

A case of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T‐cell lymphoma

JEADV Clinical Practice
A 65‐year‐old Japanese woman with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T‐cell lymphoma, a rare type with a poor prognosis, is presented.
Tomomichi Shimizu, Nobuhiro Takahashi, Aya Okaniwa, Reiko Saito, Akio Kondoh, Fumikazu Yamazaki, Shunsuke Nagase, Naoya Nakamura, Kazuya Takeuchi, Tomotaka Mabuchi   +9 more
doaj   +1 more source

Mycosis Fungoides: A Diagnostic Challenge

International Journal of Medical Students, 2022
Background: Mycosis fungoides (MF) is the most frequent type of cutaneous T-cell lymphomas (CTCL), a heterogeneous group of non-Hodgkin lymphoma of T-cell origin. CTCLs accounts for about 4% of all non-Hodgkin lymphoma.
Siddhartha Nath, Arunima Dhabal, Indrashis Podder   +2 more
doaj  

Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study

The Journal of Dermatology, EarlyView.
ABSTRACT Topical bexarotene 1% gel is an approved skin‐directed treatment for refractory or persistent stage IA‐IB cutaneous T‐cell lymphoma, but real‐world evidence in mycosis fungoides (MF), particularly regarding maintenance use after complete response, remains limited.
Fatich Memet, Dilek Bayramgürler, Abdullah Demirbaş, Evren Odyakmaz Demirsoy, Aysun Şikar Aktürk, Nilgün Sayman, Rebiay Kıran   +6 more
wiley   +1 more source

T-Cell Lymphoblastic Lymphoma with Cutaneous Involvement in a Child: A Rare Case Report

Clinical, Cosmetic and Investigational Dermatology, 2022
Jiaoquan Chen,* Xin Tian,* Nanji Yu, Liqian Peng, Huilan Zhu Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, 510095, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huilan Zhu,
Chen J, Tian X, Yu N, Peng L, Zhu H
doaj  

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

The Inverse Koebner Phenomenon in Cutaneous T‐Cell Lymphomas

JEADV Clinical Practice, EarlyView.
Alba Guglielmo, Corrado Zengarini, Alessandro Borghi, Alessandro Pileri   +3 more
wiley   +1 more source

Type‐2‐Inflammatory‐Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 Blockade

Allergy, EarlyView.
Studies suggest that type 2 inflammatory diseases are driven by overactivation of the IL4/IL13 pathway, manifesting differently in distinct tissues. We performed quantitative analyses using several large independent datasets to explore the interrelation of type 2 inflammatory diseases based on co‐prevalence, genetic predispositions, and transcriptomic ...
Jennifer D. Hamilton, Manuel A. R. Ferreira, Wei Keat Lim, Carlo Sidore, Matthew F. Wipperman, Wenzhen Ge, Xue Song, Changming Xia, Julie E. Horowitz, Andrea T. Hooper, Sara C. Hamon, Jennifer Maloney, Jamie M. Orengo, Zhen Chen, Stephanie Amato Ricci, Bolanle Akinlade, Aris Baras, Gary Herman, Brandy L. Bennett, George D. Yancopoulos   +19 more
wiley   +1 more source

A Response to “The Inverse Koebner Phenomenon in Cutaneous T‐Cell Lymphomas”

JEADV Clinical Practice, EarlyView.
Isabel Hariri, Alexander H. Enk, Jessica C. Hassel   +2 more
wiley   +1 more source

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Diffuse Skin Sclerosis in a Patient With Lung Cancer

JEADV Clinical Practice, EarlyView.
Anna‐Sophia Leven, Eva Hadaschik, Alpaslan Tasdogan   +2 more
wiley   +1 more source